Scarica l'app Stockscreener
8.53
5.54%
-0.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SGHT Giù?
Forum
Previsione
Sight Sciences Inc Borsa (SGHT) Ultime notizie
A proposed $268K share sale at Sight Sciences (SGHT) includes an amount to cover an equity-award tax bill. - Stock Titan
An officer proposes selling 7,797 Sight Sciences (SGHT) shares, including an amount to cover taxes. - Stock Titan
Sight Sciences, Inc. Announces Commercial Availability Of OMNI Ultra Surgical System And Previews Clearance Assistant Plus At AAO - marketscreener.com
Sight Sciences launches OMNI Ultra surgical system for glaucoma By Investing.com - Investing.com Canada
Sight Sciences to Debut the OMNI Ultra® Surgical System, - GlobeNewswire
Form 144 Sight Sciences For: 30 September By Investing.com - Investing.com Nigeria
Former officer Jeremy Hayden proposes selling 22,254 Sight Sciences (SGHT) shares. - Stock Titan
Sight Sciences stock gains as William Blair raises its rating - AD HOC NEWS
Sight Sciences stock holds steady as investors await next earnings update - AD HOC NEWS
SGHTSight Sciences Inc Volatility & Greeks - Finviz
Sight Sciences Inc (NASDAQ: SGHT) Share Price, SGHT Stock News, SGHT Share Price & Updates - Kalkine
Sight Sciences stock holds steady as investors watch recent ophthalmology results - AD HOC NEWS
Former Sight Sciences (SGHT) officer lines up more stock sales - Stock Titan
Sight Sciences stock holds steady as investors watch growth metrics - ad-hoc-news.de
Morgan Stanley healthcare talk featuring Sight Sciences will stream live Sept. 15 - Stock Titan
Former Sight Sciences (NASDAQ: SGHT) officer lines up more share sales after a string of summer trades - Stock Titan
Price to sales forward of Sight Sciences, Inc. – NASDAQ:SGHT - TradingView
Sight (SGHT) Q2 2026 Scorecard: EPS Beats Its Estimate at the Close; Share Move: Shares Close 1.45% Higher on the DayConsensus Beat Rate - careplusvn.com
FDA Broadens ‘Indications for Use’ for Sight Sciences’ TearCare System - VisionMonday.com
Sight Sciences Announces FDA Expanded Indication for TearCare to Improve Meibomian Gland Function in Evaporative Dry Eye Disease - Quiver Quantitative
TearCare Becomes the First and Only MGD Treatment Indicated - GlobeNewswire
GSA Capital Partners LLP Makes New Investment in Sight Sciences, Inc. $SGHT - MarketBeat
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease - The Manila Times
FDA recalls over 39K bottles of CLEAR EYES Maximum Itchy Relief drops - Glance by Eyes On Eyecare
A Quick Look at Today's Ratings for Sight Sciences(SGHT.US), With a Forecast Between $8 to $12 - Moomoo
Sight Sciences Earnings Call Shows Growth And Discipline - TipRanks
Sight Sciences (NASDAQ: SGHT) holder to sell 12,014 shares - Stock Titan
Sight Sciences (SGHT) Pulls Back to $8.14: Range-Bound Move Tests Key Support ZoneVol Target Rebalance - vinanet.vn
Sight Sciences (SGHT) insider plans 48,000-share stock sale after option exercise - Stock Titan
SGHT (SGHT) holder files to sell 2,500 shares after stock vesting - Stock Titan
Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript - AOL.com
SGHT insider Jeremy Hayden files Form 144 for recent and planned stock sales - Stock Titan
SGHT Q2 2026 Earnings: Narrowed Loss Beats Estimates, Shares Jump 6.49%Earnings Turnaround - Vinanet
SGHT (NASDAQ: SGHT) insider Jeremy Hayden plans $165,878 stock sale - Stock Titan
Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down By Investing.com - Investing.com Australia
Sight Sciences Names Kashif Rashid as New Chief Legal Officer Amid Leadership Change - Kalkine Media
Sight Sciences names Kashif Rashid chief legal officer, replacing Jeremy Hayden - Bitget
Sight Sciences Appoints New Chief Legal Officer Rashid - tipranks.com
Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down - Investing.com Nigeria
Form 8K Sight Sciences Inc For: 10 August By Investing.com - Investing.com Nigeria
Sight Sciences(SGHT) Stock Options Chain | Quotes & News - Moomoo
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - 富途牛牛
Sight Sciences (NASDAQ:SGHT) Rating Increased to Buy at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sight Sciences (SGHT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Revolution Medicines (RVMD) and Sight Sciences (SGHT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cytek Biosciences (CTKB) and Sight Sciences (SGHT) - The Globe and Mail
UBS Group Forecasts Strong Price Appreciation for Sight Sciences (NASDAQ:SGHT) Stock - MarketBeat
UBS Adjusts Price Target on Sight Sciences to $8 From $7, Maintains Buy Rating - marketscreener.com
Sight Sciences, Inc. Stock 12‑Month Price Target Raised to $8.6, Implies 55% Upside - TradingView
Sight Sciences Reports Second Quarter 2026 Financial Results - The Manila Times
Sight Sciences Q2 Earnings Call Highlights - MarketBeat
Sight Sciences Sees Q2 Revenue Growth, Raises 2026 Guidance - VisionMonday.com
Sight Sciences (NASDAQ:SGHT) Posts Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Sight Sciences (SGHT) Stock Sees Modest Fair Value Cut As Analysts Revisit Guidance - Yahoo Finance
Earnings call transcript: Sight Sciences raises 2026 outlook on Q2 growth, shares fall - Investing.com Nigeria
0.26%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):